Developer docs
API playgroundTry for free, no card

Search company profiles

Medicxi

Full company profile

uuid00009ui

Namestring
Medicxi
Legal namestring
Medicxi Ventures (UK) LLP
Websiteurl
medicxi.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Medicxi is a London-headquartered venture capital firm specializing in European life sciences investing, founded in 2016 when the life sciences team spun out of Index Ventures. The firm pioneered the 'asset-centric' investment model, which concentrates capital and resources on single-molecule or single-asset biotech companies structured as virtual operations, in contrast to traditional multi-asset biotech platforms. Medicxi manages a series of complementary funds spanning the development continuum: early-stage vehicles (Medicxi Ventures 1 / MV1, Medicxi III, Medicxi IV, Fund V) and the late-stage Medicxi Growth 1 (MG1), with cumulative fundraising exceeding €1.8 billion and the most recent Fund V closing at €500 million in November 2025.

The firm's portfolio spans 91 biotech companies across modalities and therapeutic areas, with 32 realized exits to date including Genmab, Micromet (acquired by Amgen), Molecular Partners, and recent 2025-2026 transactions such as Vicebio (acquired by Sanofi for up to $1.6 billion), Curevo and Centessa Pharmaceuticals (acquired by Eli Lilly), and RAPT Therapeutics (acquired by GSK). Cornerstone limited partners include major pharmaceutical companies—GSK, Novartis, Johnson & Johnson Innovation-JJDC, and Verily (Alphabet)—alongside the European Investment Fund, providing both capital and scientific advisory support. The leadership team includes co-founders Francesco De Rubertis, David Grainger, Kevin Johnson, and Michèle Ollier, augmented by Partner Moncef Slaoui (former GSK Chairman of Pharmaceutical R&D) and Venture Partners Sandy Zweifach and Paul Sekhri.

Medicxi generates revenue through conventional fund management economics—recurring management fees on committed and deployed capital across its fund vintages, plus carried interest on realized exits. The firm identifies and backs biotech entrepreneurs and drug hunters through direct scientific networks, industry conferences, and pharma partnerships, with offices in London, Geneva, and St Helier (Jersey). Its core differentiation is the asset-centric thesis: by isolating single assets in focused capital structures, Medicxi argues it achieves superior capital efficiency, faster decision-making, and clearer exit pathways versus traditional biotech venture models.

Short descriptiontext

Medicxi is a London-based life sciences venture capital firm founded in 2016, managing over €1.8 billion across early- and late-stage biotech funds using an asset-centric investment model. It serves biotech entrepreneurs in Europe and has executed 32 exits including Vicebio ($1.6B) and Micromet.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech investment funds, asset-centric investing, pharmaceutical growth capital, early-stage biotech financing
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital — Life Sciences Investment
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeManaged Services
Description

Generates revenue through management fees and carried interest from venture funds focused on life sciences investments.

medicxi.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Medicxi Growth 1 (MG1)
Description

Late-stage growth fund focused on European biotech companies with Phase II or beyond clinical assets

medicxi.com
+1 more record
Core offering1 text field

Medicxi is a European life sciences venture capital firm that manages multiple dedicated investment funds spanning early-stage to late-stage biotech investments. The firm employs an asset-centric investment model, backing single-asset virtual biotech companies to maximize capital efficiency in drug development across discovery, clinical proof-of-concept, and late-stage regulatory phases.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Medicxi is a European life sciences venture capital firm offering an integrated platform of investment funds spanning early-stage to late-stage biotech investments. The firm manages multiple dedicated life sciences funds: Medicxi Ventures 1 (MV1) at €210 million for early-stage investments, Medicxi Growth 1 (MG1) at $300 million for late-stage companies with Phase II+ assets, Medicxi III at €400 million for discovery through late-stage assets, and Fund V at €500 million as its most recent oversubscribed fund. The firm employs an asset-centric investment model that focuses on virtual, single-asset companies to maximize capital efficiency in drug development.

Product and service5 records
1Medicxi Ventures 1 (MV1)
CategoryVenture Capital Fund
Description

A €210 million early-stage venture fund that predominantly invests in European life sciences companies following the asset-centric strategy.

2Medicxi Growth 1 (MG1)
CategoryVenture Capital Fund
Description

A $300 million late-stage growth fund focused on European biotech companies with at least one asset in Phase II or beyond clinical development.

3Medicxi III Fund
CategoryVenture Capital Fund
Description

A €400 million fund that invests across the full healthcare continuum from discovery to late-stage clinical assets, supporting scientific entrepreneurs and drug hunters.

4Medicxi IV Fund
CategoryVenture Capital Fund
Description

A $400 million fund continuing the asset-centric biotech investment strategy.

5Medicxi Fund V
CategoryVenture Capital Fund
Description

A €500 million oversubscribed venture fund that continues the asset-centric investment strategy in biotechnology companies, supporting drug development across all development stages.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Dr Moncef Slaoui
Strategic tierCoreTypeOthers
Description

Former GSK Chairman of Pharmaceutical R&D and Vaccines. Joined as Partner in 2017, bringing extensive clinical and leadership experience. Also serves on Scientific Advisory Boards.

medicxi.com
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Atlas Venture is a Boston- and London-based venture firm focused on building early-stage biotech companies, often around single-asset platforms. Directly comparable to Medicxi in asset-centric philosophy, fund size, and European/US dual presence.

TypeDirect peer
Description

Forbion is a leading European life sciences venture capital firm managing multiple funds across early and late-stage biotech. Directly comparable to Medicxi in European life sciences focus, fund scale, and portfolio construction approach.

TypeDirect peer
Description

Sofinnova is one of Europe's longest-standing life sciences venture capital firms, investing across therapeutic platforms with similar fund vintages. Comparable to Medicxi in European focus, life sciences specialization, and clinical-stage asset orientation.

TypeDirect peer
Description

Novo Holdings' venture arm manages multi-billion life sciences investments with similar European and US life sciences mandate. Comparable to Medicxi in fund scale, biotech-only focus, and long-term horizon capital deployment.

TypeDirect peer
Description

Abingworth is a transatlantic life sciences investment firm with early- and late-stage strategies. Directly comparable to Medicxi in clinical-stage European biotech investing and dual-fund (venture + growth) structure.

TypeDirect peer
Description

OrbiMed is a global healthcare-dedicated investment firm across private and public markets. Comparable to Medicxi in healthcare-only mandate and clinical-stage biotech investing, though much larger in AUM and broader in mandate.

TypeDirect peer
Description

Index Ventures is the predecessor firm from which Medicxi's life sciences team spun off in 2016, retaining shared operational heritage and life sciences investing DNA. Directly comparable as the originating firm with parallel life sciences strategy.

TypeDirect peer
Description

Versant is a healthcare-focused venture firm building biotech companies across stages with Inception Sciences-style company creation. Comparable to Medicxi in clinical-stage biotech focus and company-building model.

TypeDirect peer
Description

RA Capital is a Boston-based healthcare-focused investment firm with crossover and private strategies. Comparable to Medicxi in clinical-stage life sciences investing and use of structured deals around single assets.

TypeDirect peer
Description

5AM Ventures is a US life sciences venture firm focused on early-stage biotech with company-creation expertise. Comparable to Medicxi in life sciences specialization, single-asset focus, and clinical development orientation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment61 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medicxi

Venture Capital — Life Sciences Investmentmedicxi.com

Medicxi is a London-based life sciences venture capital firm founded in 2016, managing over €1.8 billion across early- and late-stage biotech funds using an asset-centric investment model. It serves biotech entrepreneurs in Europe and has executed 32 exits including Vicebio ($1.6B) and Micromet.

What Medicxi does

Medicxi is a London-headquartered venture capital firm specializing in European life sciences investing, founded in 2016 when the life sciences team spun out of Index Ventures. The firm pioneered the 'asset-centric' investment model, which concentrates capital and resources on single-molecule or single-asset biotech companies structured as virtual operations, in contrast to traditional multi-asset biotech platforms. Medicxi manages a series of complementary funds spanning the development continuum: early-stage vehicles (Medicxi Ventures 1 / MV1, Medicxi III, Medicxi IV, Fund V) and the late-stage Medicxi Growth 1 (MG1), with cumulative fundraising exceeding €1.8 billion and the most recent Fund V closing at €500 million in November 2025.

The firm's portfolio spans 91 biotech companies across modalities and therapeutic areas, with 32 realized exits to date including Genmab, Micromet (acquired by Amgen), Molecular Partners, and recent 2025-2026 transactions such as Vicebio (acquired by Sanofi for up to $1.6 billion), Curevo and Centessa Pharmaceuticals (acquired by Eli Lilly), and RAPT Therapeutics (acquired by GSK). Cornerstone limited partners include major pharmaceutical companies—GSK, Novartis, Johnson & Johnson Innovation-JJDC, and Verily (Alphabet)—alongside the European Investment Fund, providing both capital and scientific advisory support. The leadership team includes co-founders Francesco De Rubertis, David Grainger, Kevin Johnson, and Michèle Ollier, augmented by Partner Moncef Slaoui (former GSK Chairman of Pharmaceutical R&D) and Venture Partners Sandy Zweifach and Paul Sekhri.

Medicxi generates revenue through conventional fund management economics—recurring management fees on committed and deployed capital across its fund vintages, plus carried interest on realized exits. The firm identifies and backs biotech entrepreneurs and drug hunters through direct scientific networks, industry conferences, and pharma partnerships, with offices in London, Geneva, and St Helier (Jersey). Its core differentiation is the asset-centric thesis: by isolating single assets in focused capital structures, Medicxi argues it achieves superior capital efficiency, faster decision-making, and clearer exit pathways versus traditional biotech venture models.

Medicxi firmographics

Firmographics
Name
Medicxi
Legal name
Medicxi Ventures (UK) LLP
Website
https://medicxi.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Medicxi is a London-based life sciences venture capital firm founded in 2016, managing over €1.8 billion across early- and late-stage biotech funds using an asset-centric investment model. It serves biotech entrepreneurs in Europe and has executed 32 exits including Vicebio ($1.6B) and Micromet.
Ownership category
akta.pro rank

Medicxi industry classification

Industry
Product category
Venture Capital — Life Sciences Investment
NAICS
Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Life sciences venture capital
  • Biotech investment funds
  • Asset-centric investing
  • Pharmaceutical growth capital
  • Early-stage biotech financing

Where Medicxi is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Medicxi business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

  1. Fund Management: Generates revenue through management fees and carried interest from venture funds focused on life sciences investments.

Go-to-market motion1 record

Marketing channels4 records

Medicxi product offering

Product offering

Core offering

Medicxi is a European life sciences venture capital firm that manages multiple dedicated investment funds spanning early-stage to late-stage biotech investments. The firm employs an asset-centric investment model, backing single-asset virtual biotech companies to maximize capital efficiency in drug development across discovery, clinical proof-of-concept, and late-stage regulatory phases.

Product overview

Medicxi is a European life sciences venture capital firm offering an integrated platform of investment funds spanning early-stage to late-stage biotech investments. The firm manages multiple dedicated life sciences funds: Medicxi Ventures 1 (MV1) at €210 million for early-stage investments, Medicxi Growth 1 (MG1) at $300 million for late-stage companies with Phase II+ assets, Medicxi III at €400 million for discovery through late-stage assets, and Fund V at €500 million as its most recent oversubscribed fund. The firm employs an asset-centric investment model that focuses on virtual, single-asset companies to maximize capital efficiency in drug development.

Differentiator

Problem solved

Functional benefit

Brands

  • Medicxi Growth 1 (MG1): Late-stage growth fund focused on European biotech companies with Phase II or beyond clinical assets
  • Medicxi Ventures 1 (MV1)

Products and services

  • Medicxi Ventures 1 (MV1) A €210 million early-stage venture fund that predominantly invests in European life sciences companies following the asset-centric strategy.
  • Medicxi Growth 1 (MG1) A $300 million late-stage growth fund focused on European biotech companies with at least one asset in Phase II or beyond clinical development.
  • Medicxi III Fund A €400 million fund that invests across the full healthcare continuum from discovery to late-stage clinical assets, supporting scientific entrepreneurs and drug hunters.
  • Medicxi IV Fund A $400 million fund continuing the asset-centric biotech investment strategy.
  • Medicxi Fund V A €500 million oversubscribed venture fund that continues the asset-centric investment strategy in biotechnology companies, supporting drug development across all development stages.

Companies that use Medicxi

Customer profile

Named customers8 records

Segments2 records

Ideal customer profiles3 records

Medicxi technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Medicxi partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Dr Moncef SlaouicoreOthersFormer GSK Chairman of Pharmaceutical R&D and Vaccines. Joined as Partner in 2017, bringing extensive clinical and leadership experience. Also serves on Scientific Advisory Boards.

Scale indicators7 records

Recent moves10 records

Expansion highlights5 records

Medicxi competitors and assessment

Company assessment

Direct peers

  • Atlas Venture: Atlas Venture is a Boston- and London-based venture firm focused on building early-stage biotech companies, often around single-asset platforms. Directly comparable to Medicxi in asset-centric philosophy, fund size, and European/US dual presence.
  • Forbion: Forbion is a leading European life sciences venture capital firm managing multiple funds across early and late-stage biotech. Directly comparable to Medicxi in European life sciences focus, fund scale, and portfolio construction approach.
  • Sofinnova Partners: Sofinnova is one of Europe's longest-standing life sciences venture capital firms, investing across therapeutic platforms with similar fund vintages. Comparable to Medicxi in European focus, life sciences specialization, and clinical-stage asset orientation.
  • Novo Holdings (Novo Ventures): Novo Holdings' venture arm manages multi-billion life sciences investments with similar European and US life sciences mandate. Comparable to Medicxi in fund scale, biotech-only focus, and long-term horizon capital deployment.
  • Abingworth: Abingworth is a transatlantic life sciences investment firm with early- and late-stage strategies. Directly comparable to Medicxi in clinical-stage European biotech investing and dual-fund (venture + growth) structure.
  • OrbiMed: OrbiMed is a global healthcare-dedicated investment firm across private and public markets. Comparable to Medicxi in healthcare-only mandate and clinical-stage biotech investing, though much larger in AUM and broader in mandate.
  • Index Ventures: Index Ventures is the predecessor firm from which Medicxi's life sciences team spun off in 2016, retaining shared operational heritage and life sciences investing DNA. Directly comparable as the originating firm with parallel life sciences strategy.
  • Versant Ventures: Versant is a healthcare-focused venture firm building biotech companies across stages with Inception Sciences-style company creation. Comparable to Medicxi in clinical-stage biotech focus and company-building model.
  • RA Capital Management: RA Capital is a Boston-based healthcare-focused investment firm with crossover and private strategies. Comparable to Medicxi in clinical-stage life sciences investing and use of structured deals around single assets.
  • 5AM Ventures: 5AM Ventures is a US life sciences venture firm focused on early-stage biotech with company-creation expertise. Comparable to Medicxi in life sciences specialization, single-asset focus, and clinical development orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Medicxi social profiles

Digital presence

Medicxi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medicxi leadership team

Management profile

Number of profiles

Profiles13 records

Medicxi funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medicxi M&A and investment

M&A and investment

M&A

Investments61 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicxi

What does Medicxi do?

Medicxi is a European life sciences venture capital firm that manages multiple dedicated investment funds spanning early-stage to late-stage biotech investments. The firm employs an asset-centric investment model, backing single-asset virtual biotech companies to maximize capital efficiency in drug development across discovery, clinical proof-of-concept, and late-stage regulatory phases.

Is Medicxi a public or private company?

Medicxi is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Medicxi founded?

Medicxi was founded in 2016. It employs 11 to 50 people.

Where is Medicxi based?

Medicxi is headquartered in London, United Kingdom, in the Europe region.

How does Medicxi make money?

One revenue line is on record: fund Management.

Who are Medicxi's main competitors?

Direct peers on record are Atlas Venture, Forbion, Sofinnova Partners, Novo Holdings (Novo Ventures), Abingworth, OrbiMed, Index Ventures, Versant Ventures, RA Capital Management and 5AM Ventures.

Does Medicxi have an API?

No public API is recorded for Medicxi.

What industry is Medicxi in?

Medicxi's product category is Venture Capital — Life Sciences Investment. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 523940 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAltesa BioSciences Named Recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the YearAltesa BioSciences was named recipient of the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year for its oversubscribed $75 million Series B financing. The round, led by Forbion with Sanofi participation, supports development of vapendavir, an antiviral for COPD, and will be presented at the August 25 summit in Sandy Springs, GA.MorningstarAltesa BioSciences Named Recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the YearAltesa BioSciences was named recipient of the 2026 Georgia Life Sciences Golden Helix Award for Financing Deal of the Year. The award recognizes its oversubscribed $75 million Series B financing led by Forbion, which supports its lead asset vapendavir for COPD and asthma. The company will present the award at the Georgia Life Sciences Summit on August 25.pharmaphorumWhich biotechs have raised new VC financing this week?Vaderis Therapeutics raised $152 million in second-round financing to fund its phase 3 trial of engasertib for hereditary haemorrhagic telangiectasia. Aureka Biotechnologies closed a $100 million Series B, Epicrispr raised $90 million, Infinimmune added $75 million, and Boulevard Bio emerged with $65 million.European BiotechnologySwiss biotech Vaderis raises $152M to take first HHT-specific therapy into Phase 3Vaderis Therapeutics raised $152 million in a Series B round to advance engasertib into Phase 3 for hereditary hemorrhagic telangiectasia. The financing, led by Goldman Sachs Alternatives and TCGX, supports the first HHT-specific therapy, with positive proof-of-concept data. The company aims to secure regulatory approval and commercialization.FinSMEsVaderis Therapeutics Raises $152M in Series B FundingVaderis Therapeutics raised $152M in Series B funding led by Goldman Sachs Alternatives and TCGX. The company will use the funds for operations, regulatory submissions, and its Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia.PR NewswireVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics closed a $152 million Series B financing and initiated the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia. The study is randomized, double-blind, placebo-controlled, and expected to enroll patients across North America, South America, and Europe. Proceeds will fund operations through regulatory submissions and potential U.S. approval.BioWorldVaderis grabs $152M series B for HHT phase IIIVaderis Therapeutics closed an oversubscribed $152 million series B to advance engasertib (VAD-044) for hereditary hemorrhagic telangiectasia. The round was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors.Tech TimesHHT Patients Get First Phase 3 Drug Trial After 130 Years Without TreatmentVaderis Therapeutics closed a $152 million Series B and launched HEROIC, the first global Phase 3 trial for engasertib in hereditary hemorrhagic telangiectasia. The drug showed a 41% reduction in bleeding duration in a prior proof-of-concept study. The trial aims to secure the first FDA approval for HHT.NewswireVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics closed a $152 million Series B financing and initiated the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia. The study is randomized, double-blind, placebo-controlled, and expected to enroll patients across North America, South America, and Europe. Proceeds will fund operations through regulatory submissions and potential U.S. approval.BioSpaceVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic TelangiectasiaVaderis Therapeutics closed a $152 million Series B financing and initiated the global Phase 3 HEROIC study of engasertib for hereditary hemorrhagic telangiectasia. The study is randomized, double-blind, placebo-controlled, and expected to enroll patients across North America, South America, and Europe. Proceeds will fund operations through regulatory submissions and potential U.S. approval.